Regulation · United States

Is retatrutide legal
in the US?

Retatrutide is an investigational Eli Lilly drug that FDA has not approved for any use. FDA has said what that means for compounded versions and for products labelled for research. Here is the agency’s own wording and the dated record.

Short answerRegulation · 7 min read · Updated 18 Nov 2026

Retatrutide is not approved by FDA for any use, and FDA says it “cannot be used in compounding under federal law”. It is an investigational Eli Lilly drug, approved nowhere. FDA warning letters from December 2024 to August 2026 list products sold as retatrutide, including ones labelled for research use, among unapproved new drugs under federal drug law.

Key takeaways

  • FDA says retatrutide “cannot be used in compounding under federal law”, is not a component of any FDA-approved drug and has “not been found safe and effective for any condition” (page current as of 1 Oct 2026).
  • Compounded retatrutide does not qualify for the section 503A or 503B exemptions, FDA wrote in September 2025: it has no USP or NF monograph, is not a component of an approved drug, and is on neither bulks list.
  • FDA says it has warned companies that illegally sold unapproved drugs containing retatrutide that were “falsely labeled ‘for research purposes’ or ‘not for human consumption.’”
  • Retatrutide is not a federally controlled substance, Drugs@FDA lists no application for it, and it is not among the six peptides in HHS’s October 2026 compounding policy (18 Nov 2026).
  • Lilly says it plans to submit a Biologics License Application to FDA in the first quarter of 2027. A submission asks FDA to review the evidence; it is not an approval.

01What does FDA say about retatrutide?

The Food and Drug Administration (FDA) has not approved retatrutide for any use. Its page on unapproved GLP-1 drugs, current as of 1 October 2026, sets out its position.

“Retatrutide and cagrilintide cannot be used in compounding under federal law. Additionally, these are not components of FDA-approved drugs and have not been found safe and effective for any condition.”

The same page says FDA has warned telehealth companies “for marketing unapproved drugs such as retatrutide, including instances of direct marketing to consumers”, active pharmaceutical ingredient distributors “for selling retatrutide and other GLP-1 drugs to compounders”, and outsourcing facilities “for repackaging retatrutide”.

On research labels it says: “FDA has warned companies that have illegally sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide that are falsely labeled ‘for research purposes’ or ‘not for human consumption.’” FDA adds that these products “have been sold directly to consumers for human use with dosing instructions”, and calls them products “of unknown quality”.

Retatrutide is an investigational Eli Lilly drug, approved nowhere. What its trials measured is in our retatrutide research guide; the other compound in FDA’s sentence is covered in our cagrilintide guide.

02Why can’t retatrutide be compounded?

Compounded drugs are not FDA approved. A pharmacy or outsourcing facility may make them only within the conditions of sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act), and both limit the bulk ingredients that may be used.

In a warning letter of 9 September 2025 to a telehealth website, FDA set out why retatrutide falls outside both routes:

SectionWhat the bulk ingredient must beWhat FDA wrote about retatrutide
503A (state-licensed pharmacies and physicians)Subject of a USP or NF monograph, a component of an FDA-approved drug, or on the 503A bulks list“retatrutide is not the subject of an applicable USP or NF monograph, is not a component of an FDA-approved human drug, and does not appear on the 503A bulks list”
503B (outsourcing facilities)On the 503B bulks list, or used for a drug on FDA’s drug shortage list“retatrutide does not appear on the 503B bulks list, and is not used to compound a drug that appears on the drug shortage list”

FDA concluded that the website’s compounded retatrutide products were “unapproved new drugs and misbranded drugs”. The 503A bulks list itself, 21 CFR 216.23, names six substances, and retatrutide is not one of them (eCFR, issue of 12 November 2026). Nor is it in any category of FDA’s list of bulk substances nominated for 503A compounding (list updated 14 May 2026).

The HHS policy. In October 2026 the Department of Health and Human Services set out an enforcement-discretion policy for 503A compounding with six peptides: BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500. Retatrutide is not on that list. More: the HHS policy explained and FDA peptide categories.

03What do FDA warning letters say about retatrutide?

Warning letters are FDA’s formal notices of violations. Three sets that we read name retatrutide.

DateRecipientWhat FDA wrote
10 Dec 2024An online seller (letter 695607)Lists “Retatrutide” (or “Reta”), with semaglutide, cagrilintide, tirzepatide and mazdutide products, as unapproved new drugs under sections 505(a) and 301(d) of the FD&C Act, though labelled “RESEARCH USE ONLY” and “INTENDED AS A RESEARCH CHEMICAL ONLY”
9 Sep 2025A telehealth website (letter 712126)Its compounded retatrutide products are “unapproved new drugs and misbranded drugs”; “There are no FDA-approved applications on file for your compounded retatrutide drug products.”
24 Aug 2026Four online sellers (letters 735067, 733652, 735127, 734884)List products sold as “Retatrutide (GLP-3 RT)”, “GLP-3 RT (Retatrutide) Research Peptide”, “GLP-3R” and “Retatrutide” among unapproved new drugs under section 505(a), each labelled for research use

The letters rest on the same rule. In FDA’s words in letter 695607, new drugs “may not be legally introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect”. On the research labels, letter 735067 says that despite statements such as “research use only”, “evidence obtained from your website establishes that your products are intended to be drugs for human use.”

“GLP-3” is a seller label recorded in FDA letters. How labels and lab reports relate: what “research use only” means.

04Is retatrutide a controlled substance or an approved drug?

Controlled substances. No. Retatrutide does not appear in the federal schedules of controlled substances, 21 CFR Part 1308 (eCFR, issue of 12 November 2026). Its status turns on drug law, not drug scheduling.

Approved drugs. Drugs@FDA, queried through openFDA for the active ingredient retatrutide, returned no match on 18 November 2026. The same query for tirzepatide, the active ingredient of approved prescription medicines, returned 2 application records.

Federal Register. A full-text search for “retatrutide” returned no documents on 18 November 2026; the same search for “tirzepatide” returned 16.

The wider US rules for peptides are on peptides and US law.

05What changed recently?

The US steps that name retatrutide, in order.

DateWhat happenedSource
10 Dec 2024FDA warning letter lists a retatrutide product, labelled for research use, among unapproved new drugsFDA letter 695607
9 Sep 2025FDA warning letter on compounded retatrutide offered by a telehealth websiteFDA letter 712126
24 Aug 2026Warning letters to four online sellers list retatrutide productsFDA letters
29 Sep 2026Lilly says it “plans to submit a Biologics License Application (BLA) in Q1 2027” to FDALilly release
1 Oct 2026FDA’s GLP-1 page, current as of this date, says retatrutide “cannot be used in compounding under federal law”FDA web page
30 Oct 2026HHS’s peptide compounding policy, noticed in the Federal Register, covers six peptides; retatrutide is not one of themHHS; Federal Register

A submission asks FDA to review the evidence. It is not an approval, and any change in status would come from FDA’s decision, not from the filing.

06How is retatrutide treated in sport?

US drug law has no bearing on anti-doping rules. WADA’s Prohibited List does not name retatrutide, in the 2026 List or in the 2027 List in force from 1 January 2027. Class S0 covers pharmacological substances with “no current approval by any governmental regulatory health authority for human therapeutic use”, WADA’s notes on the 2027 List say a peptide not specifically named “may still be prohibited”, and anti-doping organisations decide how it applies. We draw no conclusion for retatrutide here. More: is retatrutide banned in sport?

07What we don’t know

  • Whether FDA will approve retatrutide, when, or for what. Lilly’s stated plan is a submission in the first quarter of 2027.
  • Every FDA letter that names retatrutide. FDA’s letter database is not fully searchable by our tools, and its GLP-1 page refers to letters to API distributors and outsourcing facilities that we have not read. FDA correspondence with state medical boards on compounded retatrutide, reposted by state boards, could not be opened by our tools.
  • What happened after the letters. We have not tracked responses or close-outs.
  • State rules. State boards license pharmacies and prescribers; we have not researched state actions that name retatrutide.

For the UK and Australia: is retatrutide legal in the UK? and is retatrutide legal in Australia? Changes are logged in our regulatory changelog.

This is a plain-English summary of public documents, checked on 18 Nov 2026. It is not legal advice.

RefSources

  1. U.S. Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss. Web page, content current as of 1 Oct 2026; read 18 Nov 2026. www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-u…
  2. U.S. Food and Drug Administration, CDER. Warning letter 695607 (Summit Research Peptides). Warning letter, 10 Dec 2024; read 18 Nov 2026. www.fda.gov/inspections-compliance-enforcement-and-criminal-…
  3. U.S. Food and Drug Administration, CDER. Warning letter MARCS-CMS 712126 (telehealth website; compounded retatrutide). Warning letter, 9 Sep 2025; read 18 Nov 2026. www.fda.gov/inspections-compliance-enforcement-and-criminal-…
  4. U.S. Food and Drug Administration, CDER. Warning letters 735067 (TXP Innovations LLC dba Tex Peptides), 733652 (NuScience Peptides LLC), 735127 (Peak Performance Peptides) and 734884 (Royal Peptides LLC). Warning letters, all dated 24 Aug 2026; 735067 read 18 Nov 2026. www.fda.gov/inspections-compliance-enforcement-and-criminal-…
  5. U.S. Food and Drug Administration. Drugs@FDA via openFDA: active ingredient “retatrutide”, no match (control: tirzepatide, 2 application records). Database query, 18 Nov 2026. api.fda.gov/drug/drugsfda.json?search=products.active_ingred…
  6. 21 CFR 216.23 (503A bulks list) and 21 CFR Part 1308 (schedules of controlled substances). Code of Federal Regulations, eCFR issue of 12 Nov 2026; full text searched 18 Nov 2026. www.ecfr.gov/current/title-21/section-216.23
  7. U.S. Department of Health and Human Services. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances, Appendix A. Policy document, Oct 2026; hhs.gov blocks our tools, read on the Internet Archive capture of 11 Nov 2026, the newest. web.archive.org/web/20261111210456/https://www.hhs.gov/sites…
  8. Federal Register. Notice of availability of the HHS peptide policy, 91 FR 68526 (FR Doc. 2026-22192, 30 Oct 2026); and full-text searches for “retatrutide” (no documents) and “tirzepatide” (16). Federal Register API, 18 Nov 2026. www.federalregister.gov/documents/2026/10/30/2026-22192/enfo…
  9. Eli Lilly and Company. [Press release on the TRIUMPH-2 results and the planned US submission.] Press release, Indianapolis, 29 Sep 2026; read on PR Newswire 18 Nov 2026. www.prnewswire.com/news-releases/lillys-triple-agonist-retat…
  10. World Anti-Doping Agency. The 2026 Prohibited List and the 2027 Prohibited List (in force 1 Jan 2027), class S0 and index. International Standard; both PDFs downloaded from wada-ama.org and searched, 18 Nov 2026. www.wada-ama.org/sites/default/files/2026-11/2027list_en_fin…
  11. U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A (categories 1 to 3). List updated 14 May 2026; text searched for retatrutide and LY3437943, 18 Nov 2026. www.fda.gov/media/94155/download
  12. World Anti-Doping Agency. 2027 Prohibited List: summary of major modifications and explanatory notes (S0, non-approved substances). Undated (the file name carries 17 Aug 2026); published with the 2027 List on 21 Sep 2026; read at wada-ama.org 18 Nov 2026. www.wada-ama.org/sites/default/files/2026-09/2027_list_expla…

Plain-English summary of public sources, not legal or medical advice. Last checked 18 Nov 2026.

Questions

Is retatrutide FDA approved?

No. FDA says retatrutide is not a component of any FDA-approved drug and has “not been found safe and effective for any condition”. Drugs@FDA lists no application for it (18 Nov 2026).

Can pharmacies compound retatrutide?

FDA says retatrutide “cannot be used in compounding under federal law”. It has no USP or NF monograph, is not a component of an approved drug and is on neither bulks list, so compounded versions do not qualify for the 503A or 503B exemptions.

Is retatrutide a controlled substance in the US?

No. It does not appear in 21 CFR Part 1308 (eCFR, 12 Nov 2026). Its status turns on FDA drug law instead.

Does a “research use only” label change how FDA treats retatrutide?

FDA’s GLP-1 page says it has warned companies that illegally sold unapproved drugs containing retatrutide that were “falsely labeled ‘for research purposes’ or ‘not for human consumption.’” Its warning letters list such products among unapproved new drugs.

Has Lilly applied for FDA approval of retatrutide?

Lilly said on 29 September 2026 that it “plans to submit a Biologics License Application (BLA) in Q1 2027”. A submission asks FDA to review the evidence; any decision is FDA’s.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page